. Author manuscript; available in PMC: 2016 Mar 21.

Published in final edited form as: Prog Cardiovasc Dis. 2011 Jul-Aug;54(1):29–35. doi: 10.1016/j.pcad.2011.02.007

Table 4.

Summary of current guidelines for revascularization in patients with atherosclerotic RAS adapted from Hirsch et al: ACC/AHA 2006 guidelines for the management of patients with peripheral arterial disease.

Class I	Class IIa	Class IIb
1. Hemodynamically significant RAS and unexplained CHF or sudden unexplained pulmonary edema (Evidence level B)	1. Hemodynamically significant RAS and accelerated HTN, resistant HTN, HTN with unexplained unilateral small kidney and HTN with medication intolerance (Evidence level B)	1. Asymptomatic bilateral or solitary viable kidney with hemodynamically significant RAS (Evidence level C)
	2. Bilateral RAS or RAS of solitary functioning kidney and progressive CKD (Evidence level B)	2. Unilateral hemodynamically significant RAS in a viable kidney (Evidence level C)
	3. Hemodynamically significant RAS and unstable angina (Evidence level B)	3. Unilateral RAS and CKD (Evidence level C)